-
Sino Biopharmaceutical’s F-star Therapeutics Inks Third Licensing Deal with Takeda for Immunotherapies
•
Sino Biopharmaceutical Ltd (HKG: 1177) has announced a third licensing agreement between its subsidiary, F-star Therapeutics Inc., (NASDAQ: FSTX), and Japan-based Takeda Pharmaceutical Co., Ltd. The agreement facilitates the utilization of F-star’s proprietary wholly human Fcab and tetravalent mAb2 platforms to develop next-generation multi-specific immunotherapies targeting cancer. Joint Research and…
-
Sino Biopharmaceutical’s Subsidiary invoX Completes Additional Investment in pHion Therapeutics
•
The UK-based invoX Pharma Ltd, a wholly-owned subsidiary of China’s Sino Biopharmaceutical Ltd (HKG: 1177), has revealed the completion of a second tranche of investment in the Belfast-based company pHion Therapeutics. Specific details regarding the first or second tranche of investment and invoX’s current stake-holding in pHion have not been…
-
Sino Biopharmaceutical’s F-star Therapeutics Signs Second Licensing Deal with Takeda
•
Sino Biopharmaceutical Ltd (HKG: 1177) has announced a second licensing agreement between its recently acquired subsidiary, F-star Therapeutics Inc. (NASDAQ: FSTX), and Japan-based Takeda Pharmaceutical Co., Ltd (TYO: 4502). The deal provides Takeda with a next-generation tumor immunotherapy bispecific antibody (BsAb), with the specific target or other molecule details undisclosed.…
-
F-star Therapeutics’ Acquisition by invoX Pharma Cleared by CFIUS
•
UK biotech F-star Therapeutics, Inc. (NASDAQ: FSTX) has announced that it has received clearance from the Committee on Foreign Investment in the United States (CFIUS) for the all-cash acquisition by invoX Pharma Limited, a UK-based subsidiary of China’s Sino Biopharmaceutical Ltd (HKG: 1177). This clearance is a significant step towards…
